Capricor Therapeutics (CAPR) Debt to Equity (2016 - 2024)
Capricor Therapeutics has reported Debt to Equity over the past 15 years, most recently at $0.05 for Q3 2024.
- For Q3 2024, Debt to Equity rose 102.62% year-over-year to $0.05; the TTM value through Sep 2024 reached $0.05, up 102.62%, while the annual FY2023 figure was $0.15, 49.2% down from the prior year.
- Debt to Equity for Q3 2024 was $0.05 at Capricor Therapeutics, down from $0.29 in the prior quarter.
- Over five years, Debt to Equity peaked at $1.24 in Q2 2023 and troughed at -$1.89 in Q3 2023.
- A 5-year average of $0.12 and a median of $0.15 in 2023 define the central range for Debt to Equity.
- Biggest five-year swings in Debt to Equity: skyrocketed 16345.77% in 2022 and later plummeted 941.96% in 2023.
- Year by year, Debt to Equity stood at $0.12 in 2020, then rose by 5.86% to $0.13 in 2021, then soared by 131.99% to $0.29 in 2022, then tumbled by 49.2% to $0.15 in 2023, then crashed by 66.89% to $0.05 in 2024.
- Business Quant data shows Debt to Equity for CAPR at $0.05 in Q3 2024, $0.29 in Q2 2024, and $0.18 in Q1 2024.